Application of C5 inhibitors in glomerular diseases in 2021

다국어 초록 (Multilingual Abstract)

The complement pathway is an essential mechanism in innate immunity, but it is also involved in multiple pathologies. For kidney diseases, strong evidence of a dysregulation in the alternative pathway in atypical hemolytic uremic syndrome (aHUS) led to the use ofeculizumab, the first anti-C5 inhibitor available in clinical practice. Intensive fundamental research resulted in the development ofsubsequent new drugs, such as long-acting C5 inhibitors, oral medications, or antagonists of C5aR, the receptor for C5a. New data inthe domain of C5-inhibition in glomerular diseases are still limited and mainly focus on 1) the efficacy of ravulizumab, a long-actingC5 inhibitor in aHUS, and 2) the use of avacopan, a C5aR antagonist, in antineutrophil cytoplasmic antibody vasculitis. Several newstudies ongoing or planned for the next few years will evaluate the efficacy of C5 inhibition in secondary thrombotic microangiopathy,C3 glomerulopathy, membranous nephropathy, or immunoglobulin A nephropathy.

참고문헌 (Reference)

1 Menne J, "Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104 : H4 induced haemolytic uraemic syndrome : case-control study" 345 : e4565-, 2012

2 Zuber J, "Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome" 30 : 2449-2463, 2019

3 Ring T, "Use of eculizumab in crescentic IgA nephropathy : proof of principle and conundrum?" 8 : 489-491, 2015

4 Welte T, "Treating C3 glomerulopathy with eculizumab" 19 : 7-, 2018

5 Ariceta G, "The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" 100 : 225-237, 2021

6 Rondeau E, "The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" 97 : 1287-1296, 2020

7 Trouw LA, "The complement system as a potential therapeutic target in rheumatic disease" 13 : 538-547, 2017

8 Hillmen P, "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria" 355 : 1233-1243, 2006

9 Legendre CM, "Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome" 368 : 2169-2181, 2013

10 Fakhouri F, "Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome : a single-arm, open-label trial" 68 : 84-93, 2016

11 Zhang Y, "Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice" 189 : 60-70, 2017

12 Jayne D, "Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis" 28 : 2756-2767, 2017

13 Walsh M, "Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis" 382 : 622-631, 2020

14 Le Quintrec M, "Patterns of clinical response to eculizumab in patients with C3 glomerulopathy" 72 : 84-92, 2018

15 van Timmeren MM, "Pathogenesis of ANCA-associated vasculitis : recent insights from animal models" 24 : 8-14, 2012

16 Nakazawa D, "Pathogenesis and therapeutic interventions for ANCA-associated vasculitis" 15 : 91-101, 2019

17 Wingerchuk DM, "Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD" 89 : 1088-1098, 2021

18 Barbour T, "Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults" 6 : 1603-1613, 2021

19 Menne J, "Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome(aHUS)?" 97 : 1106-1108, 2020

20 El Karoui K, "Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome" 104 : 2501-2511, 2019

21 Bruel A, "Hemolytic uremic syndrome in pregnancy and postpartum" 12 : 1237-1247, 2017

22 Fakhouri F, "Haemolytic uraemic syndrome" 390 : 681-696, 2017

23 Timmermans S, "Functional and genetic landscape of complement dysregulation along the spectrum of thrombotic microangiopathy and its potential implications on clinical outcomes" 6 : 1099-1109, 2021

24 Licht C, "Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies" 87 : 1061-1073, 2015

25 Walsh M, "Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis : a meta-analysis" 62 : 1166-1173, 2010

26 Rosenblad T, "Eculizumab treatment for rescue of renal function in IgA nephropathy" 29 : 2225-2228, 2014

27 Rondeau E, "Eculizumab safety : five-year experience from the global atypical hemolytic uremic syndrome registry" 4 : 1568-1576, 2019

28 Socié G, "Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome : 10-year pharmacovigilance analysis" 185 : 297-310, 2019

29 Bomback AS, "Eculizumab for dense deposit disease and C3 glomerulonephritis" 7 : 748-756, 2012

30 Fakhouri F, "Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome : a prospective multicenter study" 137 : 2438-2449, 2021

31 Brodsky RA, "Eculizumab and aHUS : to stop or not" 137 : 2419-2420, 2021

32 Noris M, "Dynamics of complement activation in aHUS and how to monitor eculizumab therapy" 124 : 1715-1726, 2014

33 Timmermans S, "Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy" 75 : 422-430, 2020

34 Koopman J, "Deposition of the membrane attack complex in healthy and diseased human kidneys" 11 : 599974-, 2021

35 Walport MJ, "Complement. First of two parts" 344 : 1058-1066, 2001

36 Le Quintrec M, "Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation" 8 : 1694-1701, 2008

37 Zipfel PF, "Complement inhibitors in clinical trials for glomerular diseases" 10 : 2166-, 2019

38 Caravaca-Fontan F, "Complement inhibitors are useful in secondary hemolytic uremic syndromes" 96 : 826-829, 2019

39 Duineveld C, "Complement inhibitors are not useful in secondary hemolytic uremic syndromes" 96 : 829-833, 2019

40 Palma L, "Complement in secondary thrombotic microangiopathy" 6 : 11-23, 2021

41 Frémeaux-Bacchi V, "Complement gene variants and Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome : retrospective genetic and clinical study" 14 : 364-377, 2019

42 Palomo M, "Complement activation and thrombotic microangiopathies" 14 : 1719-1732, 2019

43 Xiao H, "C5a receptor(CD88)blockade protects against MPO-ANCA GN" 25 : 225-231, 2014

44 Ruggenenti P, "C5 convertase blockade in membranoproliferative glomerulonephritis : a single-arm clinical trial" 74 : 224-238, 2019

45 Smith R, "C3 glomerulopathy : understanding a rare complement-driven renal disease" 15 : 129-143, 2019

46 Kielstein JT, "Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry" 27 : 3807-3815, 2012

47 Jayne D, "Avacopan for the treatment of ANCA-associated vasculitis" 384 : 599-609, 2021

48 Le Clech A, "Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors" 95 : 1443-1452, 2019

49 Galbusera M, "An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome" 74 : 56-72, 2019

50 Merkel PA, "Adjunctive treatment with avacopan, an oral c5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis" 2 : 662-671, 2020